Amotosalen/UVA pathogen inactivation technology reduces platelet activability, induces apoptosis and accelerates clearanceWith interest we read the paper by Stivala et al., 1 recently published in Haematologica, evaluating the structural and functional consequences induced by Amotosalen/UVA treatment using the Intercept Blood System (IBS) on platelets from apheresis platelet concentrates (PCs) during storage. This study provides results of early diminished platelet function in IBS-treated PCs as compared to conventional PCs, i.e., reduced aggregation response to collagen or thrombin and adhesion to collagen or vWF under flow, increased platelet apoptosis, MAPK p38 activation, and glycoprotein Ibα (GPIbα) shedding and enhanced clearance from the circulation of mice.These results strikingly contrast with our previous published study 2 which evaluated the impact of IBS on platelets isolated from buffy coat PCs, washed and suspended in Tyrode's buffer. Surprisingly, Stivala et al.